Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

Healthcare Biotechnology
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

StageZero Life Sciences Ltd
Bullboard Posts
User Avatar Image
(42)
•••
Post by polo11on Aug 03, 2016 7:23am
144 Views
Post# 25105292

Technical analysis - Strong buy

Technical analysis - Strong buy

GENENEWS LIMITED (GEN.TO)

0.165  +0.010 (+6.452%)

8/2/2016  3:59pm 

Open:

0.160

Prev Close:

0.155

High:

0.180

Low:

0.150

Volume:

969621

Market Cap:

9.65M

52 Week High:

0.320

 52 Week Low:

0.010
 

Technical Analysis

Overall

   

        

What's this

Targets

Six months: 0.24     One year: 0.28 

Supports

Support1: 0.14    Support2: 0.12 

Resistances

Resistance1: 0.20    Resistance2: 0.24  

Pivot Point

0.16  

Moving Averages

MA(5): 0.16     MA(20): 0.16 

MA(100): 0.17     MA(250): 0.15 

MACD

MACD(12,26):     Signal(12,26,9):  

Stochastic Oscillator

%K(14,3): 27.78     %D(3): 24.07 

RSI

RSI(14): 49.10 

52-Week

High: 0.32  Low: 0.01  Change(%): -41.1

Average Volume(K)

3-Month: 342  10-Days 252

 Strong Sell  Sell  Neutral  Buy  Strong Buy
 

Price and moving averages

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
 

Bollinger Bands

GEN.TO has closed below upper band by 42.0%. Bollinger Bands are 73.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to GEN.TO's normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend. 
 

Company News

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities